Clinical outcomes and safety of polymyxin B in the treatment of carbapenem-resistant Gram-negative bacterial infections: a real-world multicenter study

Table 2 Comparison of patient conditions before and after therapy

Parameter	Baseline	After therapy	P
Heart rate, bpm, mean ± SD	92.02 ± 21.55	97.36 ± 20.35	0.895
Temperature, ℃, median (IQR)	38 (37.1, 38.7)	37.1 (36.7, 37.6)	< 0.001
WBC, × 10⁹/L, median (IQR)	14.13 (10.08, 20.02)	9.28 (7.02, 13.40)	< 0.001
PLT, × 10⁹/L, mean ± SD	111.71 ± 97.68	190.95 ± 162.99	< 0.001
CRP, ug/l, median (IQR)	103.55 (56.96, 180.83)	47.6 (13.08, 102.58)	< 0.001
PCT, ng/ml, median (IQR)	3.89 (1.09, 11.43)	1.695 (0.46, 5.41)	< 0.001
SOFA, mean ± SD	7.74 ± 4.13	7.32 ± 4.41	0.282
APACHE II, mean ± SD	17.75 ± 7.69	15.98 ± 7.95	0.007
Mechanical ventilation, n (%)	51	26	< 0.001
Septic shock, n (%)	49	26	< 0.001

Categorical variables are presented as numbers (%), and continuous variables are presented as mean ± SD or interquartile ranges [IQR]
WBC: white blood cell; CRP; C-reactive protein; PLT: platelet count; PCT: procalcitonin; SOFA: Sequential Organ Failure Assessment; APACHE II: Acute Physiology and Chronic Health Evaluation II; SD: standard deviation

ISSN: 1479-5876